SPI Pharma Inc. a leader in biopharmaceutical excipient and adjuvant systems, and Inimmune Corp., a biotechnology company specializing in the discovery and development of innate immune modulators, have partnered to develop and commercialize advanced adjuvant systems for vaccine development.

This collaboration leverages Inimmune’s expertise in adjuvant formulation and immunotherapeutics and SPI Pharma’s manufacturing and global commercial capabilities.

Adjuvant systems are critical components of vaccines that enhance immune response and efficacy. The partnership will aim to provide reliable supply and open access to advanced adjuvant systems, addressing significant unmet needs in vaccine development and accelerating the availability of these technologies to healthcare providers and patients globally.

“Inimmune’s dedication to advancing immunological research coupled with SPI Pharma’s robust commercial infrastructure creates a powerful synergy,” said John McInerney, Vice President of Commercial for SPI Pharma. “Together, we are poised to deliver innovative solutions that can potentially transform vaccine efficacy and patient outcomes worldwide.”

“We are excited to collaborate with SPI Pharma to bring our vaccine adjuvant technologies to market,” said Alan Joslyn, Ph.D., CEO of Inimmune. “This partnership underscores our shared commitment to improving public health through innovation.”